Get the latest tech news
Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices
Struggling small biotech firms are pivoting into cryptocurrencies, rebranding as "crypto treasuries" or stockpiling digital assets like Ether and Litecoin as a last-ditch effort to boost share prices amid stalled funding and weak drug pipelines. Bloomberg reports: Shares of 180 Life Sciences Corp.,...
Struggling small biotech firms are pivoting into cryptocurrencies, rebranding as "crypto treasuries" or stockpiling digital assets like Ether and Litecoin as a last-ditch effort to boost share prices amid stalled funding and weak drug pipelines. Bloomberg reports: Shares of 180 Life Sciences Corp., now doing business as ETHZilla, tripled after the Peter Thiel-backed company said it had accumulated Ether tokens worth over $350 million. For drugmakers it can be a sudden shift to chase after trendy new treatment targets, still other companies rebrand with buzzwords like artificial intelligence to juice returns.
Or read this on Slashdot